首页> 外国专利> PLASMID pVAX-RBD DNA MATRIX OF mRNA-RBD MOLECULES, OBTAINED USING THE pVAX - RBD DNA MATRIX, PROVIDING THE SYNTHESIS AND SECRETION OF THE RBD PROTEIN SARS-CoV 2 IN MAMMALIAN CELLS AND A COMPLEX IN THE FORM OF NANOPARTICLES CONTAINING mRNA-RBD MOLECULES THAT INDUCE SARS-CoV-SPECIFIC ANTIBODIES WITH VIRAL NEUTRALIZING ACTIVITY

PLASMID pVAX-RBD DNA MATRIX OF mRNA-RBD MOLECULES, OBTAINED USING THE pVAX - RBD DNA MATRIX, PROVIDING THE SYNTHESIS AND SECRETION OF THE RBD PROTEIN SARS-CoV 2 IN MAMMALIAN CELLS AND A COMPLEX IN THE FORM OF NANOPARTICLES CONTAINING mRNA-RBD MOLECULES THAT INDUCE SARS-CoV-SPECIFIC ANTIBODIES WITH VIRAL NEUTRALIZING ACTIVITY

机译:使用PVAX - RBD DNA基质获得的mRNA-RBD分子的质粒pVAX-RBD DNA基质,在哺乳动物细胞中提供RBD蛋白SARS-COV 2的合成和分泌,并以含mRNA-RBD分子的纳米颗粒形式的复合物 用病毒中和活性诱导SARS-COV特异性抗体

摘要

FIELD: biotechnology. ;SUBSTANCE: invention relates to biotechnology and genetic engineering. The pVAX-RBD plasmid DNA matrix was created, having a nucleotide sequence SEQ ID NO: 1 with a size of 3710 bp, a molecular weight of 2.6×103 kDa, containing the target gene encoding the chimeric protein 176-RBD, preceded by the promoter of phage T7 RNA polymerase, which provides in vitro synthesis of mRNA-RBD using T7 RNA polymerase. The mRNA-RBD molecule having the nucleotide sequence SEQ ID NO: 2 was obtained using the pVAX-RBD DNA matrix, contains an open reading frame encoding the amino acid sequence SEQ ID NO: 3, which provides synthesis and secretion of the RBD SARS-CoV 2 immunogen protein in the mammalian body, and contains a hybrid signal sequence 176, the Kozak consensus sequence, a 7-methylguanosine cap at the 5'-end of the mRNA, a polyadenosine (poly A) tail at the 3'-end of the mRNA, 150-200 nucleotides long, and 5'- and 3'-untranslated regions (UTR) before and after the open reading frame. A complex in the form of nanoparticles inducing SARS-CoV-specific antibodies with viral neutralizing activity, consisting of polyglucinepermidine conjugate molecules and mRNA-RBD molecules taken in different charge ratios from 1:1 to 1:30, corresponding to a weight ratio from 1:3 to 1:90, having a size in the range of 50-900 nanometers, and each nanoparticle contains a core consisting of mRNA-RBD molecules and coated with a layer of polyglucinepermidine conjugate retained due to the ionic interaction between a negatively charged nucleus and a positively charged spermidine. ;EFFECT: creation of a more effective means of delivering mRNA-RBD to the cells of the body for the synthesis of the RBD SARS-Cov-2 protein in them and increasing the level of secretion of this protein from the cells to ensure the presentation of the RBD protein to the immune system of the body. ;4 cl, 7 dwg, 1 tbl, 5 ex
机译:领域:生物技术。 ;物质:发明涉及生物技术和基因工程。产生pVAX-RBD质粒DNA基质,具有占尺寸为3710bp的核苷酸序列SEQ ID NO:1,分子量为2.6×103kDa,含有编码嵌合蛋白176-RBD的靶基因,前面噬菌体T7 RNA聚合酶启动子,使用T7 RNA聚合酶提供MRNA-RBD的体外合成。使用PVAX-RBD DNA基质获得具有核苷酸序列SEQ ID NO:2的mRNA-RBD分子,含有氨基酸序列SEQ ID NO:3的开放阅读框,其提供RBD SARS的合成和分泌 - COV 2在哺乳动物体中的免疫原蛋白,并含有杂交信号序列176,Kozak共有序列,MRNA的5'末端的7-甲基胍帽,在3'-末端的多腺苷(Poly A)尾在开放阅读框之前和之后的mRNA,150-200个核苷酸长和5'-和3'和3'和3'-未翻译的区域(UTR)。纳米颗粒形式的复合物,诱导具有病毒中和活​​性的SARS-COV特异性抗体,由含有聚葡氨脒酰胺缀合物分子和MRNA-RBD分子从1:1至1:30的不同电荷比例组成,对应于1的重量比:3至1:90,尺寸在50-900纳米的范围内,并且每个纳米颗粒含有由mRNA-RBD分子组成的核心,并且由于带负电荷的细胞核之间的离子相互作用而被保留的一层多林氨酰胺缀合物。和带有带电的亚精亚胺。 ;效果:创建更有效的手段,将mRNA-RBD传递给体内的细胞,以合成RBD SARS-COV-2蛋白,并增加来自细胞的该蛋白质的分泌水平以确保介绍RBD蛋白对身体的免疫系统。 ; 4 Cl,7 dwg,1 tbl,5 ex

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号